Recent advances in the application of liquid biopsy in gastrointestinal malignancies by Karczub, János
I
2Central European Journal of Gastroenterology and Hepatology
Volume 5, Issue 1 / April 2019
Összefoglaló közlemények / Reviews
Recent advances 
in the application of liquid biopsy 
in gastrointestinal malignancies
János Karczub, MD, András Budai, MD, Endre Konstek, András Kiss, MD, PhD, DSc
2nd Department of Pathology, Semmelweis University, Budapest, Hungary
Correspondence: kiss.andras@med.semmelweis-univ.hu
Liquid biopsy is an emerging diagnostic tool in medicine. That means non-invasive sampling and analysis 
of whole blood, serum, saliva and urine samples for cancer-associated particles (e.g. circulating tumor 
cells, circulating cell-free nucleotides, exosomes, cancer associated proteins, etc.). Liquid biopsy could 
develop to be a crucial step in the diagnosis and management of gastrointestinal tumors. Compared to 
currently used tissue based (core biopsy,  ne-needle aspiration biopsy, surgical resection) diagnostic 
methods it might deliver comparable information regarding molecular and genetic pro ling of tumors. 
Further, it might provide earlier diagnosis and better re ect tumor heterogeneity. Used together with 
other diagnostic modalities (e.g. imaging studies, currently used tumor markers) liquid biopsy could pro-
vide useful information for precision medicine and personalized therapy.
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A likvid biopszia új felhasználási lehetőségei gasztrointesztinális 
daganatokban
A likvid biopszia egy feltörekvő módszer az orvosi diagnosztikában. Ez noninvazív módon nyert vér-, 
nyál- és vizeletminták analízisét jelenti, különböző tumorasszociált partikulumok (pl. keringő tumor-
sejtek, keringő nukleotidok, exoszómák, tumorasszociált fehérjék) kimutatására. A likvid biopszia a 
jövőben lényeges lépéssé válhat az emésztőtraktus daganatos betegségeinek diagnosztikájában és 
kezelésében. A módszer az eddig használt szövetalapú mintavételi technikákhoz (sebészi reszekció, core 
biopszia, vékonytű-aspiráció biopszia) képest potenciálisan ugyanannyi vagy több információt tud nyújt-
hat a tumorok molekuláris és genetikai hátteréről. Ezen túlmenően koraibb diagnózist eredményező és 
a tumorheterogenitást jobban tükröző módszer lehet. Egyéb diagnosztikus eljárásokkal (pl. képalkotási 
módszerek, jelenleg is használt tumormarkerek), a likvid biopszia a precíziós orvoslás és a személyre sza-
bott terápia számára szolgálhat hasznos információkkal.
KULCSSZAVAK: likvid biopszia, gasztrointesztinális, máj, rák, vér, tumor
Introduction
Liquid biopsy in medical diagnostics is based on the 
analysis of body fl uid samples (e.g. whole blood, serum, 
urine and saliva, etc.) with the purpose of screening, di-
agnosing and monitoring diseases. Major targets are ma-
lignant tumors that are diffi  cult to detect with routinely 
applied clinical methods, such as imaging modalities and 
solid biopsy methods (fi ne-needle aspiration biopsy – 
FNAB – core biopsy). The primary advantage of this non-
invasive method when compared with imaging methods 
is the potential ability to detect malignant diseases in 
their early stages, which might not always be possible 
to accomplish due to the limited resolution of imaging 
techniques.
Samples taken via conventional biopsies are suitable for 
cytological, histological or molecular analysis and might 
serve to establish early diagnosis, identify targets for 
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therapy and determine prognosis or prediction. However, 
there is the possibility that even numerous biopsy speci-
mens do not represent the complexity of the tumor due to 
tumor heterogeneity (1).
Furthermore, early metastases might remain undetectab-
le with routine clinical methods after resection of the pri-
mary tumor. In addition, there are anatomical situations 
where conventional biopsies cannot be performed due to 
technical difficulties, while blood, saliva and urine samples 
are readily available under most circumstances. Therefore, 
body fluids could serve as non-invasive sampling for sensi-
tive detection methods. Various circulating particles, such 
as circulating tumor cells (CTCs), circulating cell-free nuc-
leotides (cfNAs), exosomes and cancer-associated proteins 
could be investigated.
Widespread use and further evaluation of the liquid bi-
opsy technique could lead to breakthroughs in cancer 
diagnostics and screening. Subsequently, early detection, 
molecular and genetic profiling of tumors could guide 
chemotherapy and targeted therapy, as well as monitoring 
patients for relapses.
The aim of this article is to review recent advances and 
methods in the application of liquid biopsies in the rese-
arch and clinical setting, mainly from the perspective of 
malignancies of the gastrointestinal tract.
Sampling of liquid biopsy
Blood/serum
Blood samples are the most common form of liquid biopsy 
by far, due to the ubiquitous nature of this sampling met-
hod. The number of studies evaluating potential blood 
biomarkers for solid tumors is ever-growing and major 
advancements have been made towards development of 
universal tumor blood biomarkers.
CancerSEEK is a multicomponent protein- and circulating 
tumor DNA (ctDNA)-based combined blood test. Based on 
the detection of somatic mutations in the eight most com-
mon solid tumors (lung, colorectum, breast, ovary, liver, 
pancreas, esophagus and stomach) and elevated plasma 
levels of eight proteins (CA-125, CEA, CA19-9, PRL, HGF, 
OPN, MPO and TIMP-1), CancerSEEK has a sensitivity of 
over 95% in detecting ovarian and liver tumors, approxi-
mately 70% for stomach, pancreatic and esophageal can-
cer, and nearly 60% for colorectal (CRC) and lung cancer 
(LC). Sensitivity for breast cancer was significantly lower. 
This study also concluded that mutations detected throu-
gh the analysis of cancer tissue biopsies were also detec-
table in the blood samples in approximately 90% of the 
cases examined (2).
Methylation patterns, the so-called Methylscape, of ge-
nomic DNA, are drastically altered in tumor cells when 
compared with non-cancerous cells. Epigenetic rep-
rogramming results in significantly higher quantities of 
5-methylcytosine in DNA derived from cancer cells. This 
changes the physical properties of purified genomic DNA 
(gDNA), leading to significant differences in the solvation 
properties of gDNA when compared with gDNA from non-
cancerous cells. Results showed that cell free DNA (cfDNA)-
derived gDNA samples of cancer cells had higher affinity 
towards bare gold surfaces in comparison to that of non-
cancerous cells. Sample pre-processing or amplification 
was not necessary in this method. Analysis of Methylscape 
could universalize detection of cancer-associated nucleo-
tides in samples irrespective of origin (e.g. plasma, tissue) 
and cancer location (3).
Saliva
Analysis of saliva samples has the potential to become a 
major tool of cancer diagnostics due to its technical simp-
licity and feasibility (4).
Detection of microRNA-21 (miR-21) was found as a plasma 
and saliva marker of colorectal cancer (CRC). Both plasma 
and saliva levels of miR-21 were elevated in saliva samp-
les taken from patients having colorectal cancer at vari-
ous stages, producing a sensitivity and specificity of 97% 
and 91%, respectively, while only 65% and 85% in plasma 
samples. Thus, in this study, saliva-based liquid biopsies 
showed higher sensitivity and specificity compared to 
plasma samples (5).
Urine
There are reported investigations for the use of urine 
samples to diagnose colorectal cancer.
Song et al. used urine samples of 150 metastatic colorectal 
cancer (mCRC) patients to analyze KRAS mutations of ctD-
NA. Concordance of 90% was found between the results 
from surgical resection specimens and urine ctDNA samp-
les regarding KRAS mutational status (6). A high concor-
dance rate between the results of invasive tissue sampling 
and non-invasive methods might lead to the reassessment 
of diagnostic and surveillance protocols.
Ascites
Ascites could serve also for liquid biopsy. Tumor-infiltra-
ting lymphocyte (TIL) profile of ascites fluid samples of pa-
tients with high-stage gastrointestinal (colorectal, gastric 
and pancreatic) tumors was studied by Nakano et al. Re-
sults of this study showed that ascites fluid TILs exhibiting 
PD-1 and/or TIM-3 positivity were indicative of poor prog-
nosis (7).
Targets of liquid biopsy
Cell-free DNA and RNA (cfDNA, cfRNA)
Circulating cell-free DNA (cfDNA) is predominantly derived 
from circulating leukocytes in blood samples, with a signi-
ficantly smaller fraction originating from circulating tumor 
cells (8, 9).
Analysis of cell-free DNA has been used in various fields, 
including prenatal screening, detection of infectious di-
seases such as EBV (HHV-8), hematological malignancies 
and for early screening for solid tumors as well (10, 11).
Analysis of circulating DNA might provide more precise in-
formation on heterogenous mutation profile of the tumor 
cells than molecular analysis of conventional biopsy. This 
feature could be useful to monitor and guide personalized, 
targeted therapy (12).
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Circulating tumor cells (CTCs)
CTCs are tumor cells detectable in blood samples which are 
associated with the presence of solid tumors. CTCs might 
exhibit similar features of the primary tumor or might ref-
lect the heterogeneity of molecular and genetic profile of 
the primary malignancy. Analysis of these potential simila-
rities and differences is one of the most contested topics 
of non-invasive tumor diagnostics. The technique might 
also allow early detection of tumor invasion (13). However, 
a major limitation to the diagnostic and prognostic utility 
of circulating tumor cells of epithelial origin is the possible 
epithelial-mesenchymal transition (EMT) of CTCs, which 
leads to loss of surface EpCAM expression (14).
Circulating microRNAs (miRs)
microRNAs (miRs) act as important factors in the negative 
regulation of gene expression. Several studies detail their 
role as oncogenic and tumor suppressor miRs as well as 
biomarkers and therapeutic targets. Further, they might 
bear predictive information on survival. They are present 
in tumor cells and also in body fluids as circulating tumor-
associated miRNAs (15).
Exosomes, extracellular vesicles
Exosomes are circulating vesicles found in numerous body 
fluids, including blood, saliva and urine (16). Exosomes 
might contain miRs, long non-coding RNAs, piwi-interac-
ting RNAs, transfer RNAs and small nuclear RNAs (17).
Proteins
Carcinoembryonic antigen (CEA) and Alpha-Fetoprorein 
(AFP) have been used as tumor markers for monitoring of 
disease progression and therapeutic efficacy in colorectal 
cancer and primary cancers of the liver, respectively (18, 
19). Cancer Antigen 19-9 (CA-19-9) has been used as a 
tumor marker primarily for pancreatic malignancies. Ho-
wever, increased plasma CA19-9 has also been associated 
with colorectal malignancies and pancreatitis (20).
Tumor markers have been widely used for monitoring 
progression and therapeutic response. However, neither 
their sensitivity nor specificity are high enough for them 
to be used as diagnostic tools. Therefore, future protein 
biomarkers of cancers must demonstrate high sensitivity 
and specificity.
Associations with microbiome changes
There is established evidence of associations between the 
presence of certain microbial agents detected in body flu-
id (e.g. blood, joint aspirate etc.) samples and asymptoma-
tic malignant tumors. Due to these associations, bacteri-
al culture and sensitivity tests in the workup of infective 
endocarditis could also be considered “preemptive” liquid 
biopsies (21, 22).
One prominent example is Streptococcus gallolyticus 
(group G Streptococcus, formerly called, Streptococcus bo-
vis) bacteremia and endocarditis, which has been shown 
to be associated with asymptomatic colorectal, pancreatic 
and biliary neoplasms. Inflammatory conditions of prost-
hetic and non-prosthetic joints with aspirates positive for 
S. gallolyticus have also been described as warning signs of 
underlying malignancies (22).
There are reports of other microbial agents, such as Strep-
tococcus viridans and Enterococcus faecalis being among 
the incidental first indicators of with hidden malignant tu-
mors, primarily colorectal carcinomas (23, 24).
Liquid biopsy of gastrointestinal tumors
Hepatobiliary tumors
Hepatocellular cancer (HCC)
Lee et al. elaborated the critical importance of genes FGF19 
and MET in the targeted therapy of hepatocellular carci-
nomas (HCCs). Detailed molecular pathological analysis 
is essential for establishing the appropriate therapeutic 
regiment, which necessitates the acquisition of several 
HCC samples. Due to tumor heterogeneity, even several 
conventional core biopsy samples may not provide repre-
sentative information about the entirety of the tumor. On 
the other hand, it was observed that liquid biopsy samples 
could better represent the mutational status of the HCCs 
examined by detecting mutations of the FGF19 and MET 
genes in cases where mutations could not be discovered 
by analysis of solid tissue biopsies alone (25).
miR-224 is an oncogenic microRNA with highly elevated 
levels in HCCs that has been described in numerous stu-
dies as a prognostic marker independent of hepatic func-
tion. Okajima et al. described that miR-224 levels in plasma 
and HCC tissue samples were significantly correlated (26). 
Elevated expression of miR-224 in HCC cells collected by 
FNAB before sorafenib treatment is associated with higher 
overall survival rates (15). Detection of miR-224 in plasma 
samples may become a method to screen for HCCs, while 
also providing valuable information prior to surgery regar-
ding possible disease outcome.
Downregulation of miR-195 expression was described as a 
phenomenon associated with the presence of HCC. Blood 
samples of 120 patients with HCC, 64 patients with hepa-
titis and 118 healthy controls were analyzed and miR-195 
levels were assessed using qRT-PCR, with relative expres-
sion of miR-196 normalized to that of miR-16. Blood levels 
of miR-195 were significantly lower in samples taken from 
HCC patients when compared with samples of patients with 
hepatitis without cancer, as well as and healthy controls. 
Samples of HCCs with concurrent hepatitis also exhibited 
lower miR-195 levels compared to that of hepatitis patients 
without cancer. HCCs with low miR-195 were associated 
with higher TNM stage, particularly the presence of lymph 
node metastases, in comparison to high miR-195 cases. The-
se results could also suggest a potential role for miR-195 as 
an agent in the targeted therapy of HCCs (27).
Low expression of beta-lactamases (LACTB) in HCCs is 
associated with tumor progression and poor prognosis. 
Based on two cohorts of 396 and 84 HCC tissue samples 
and the associated clinicopathological data, low expres-
sion of LACTB showed correlations with tumor sizes >5 
cm  and higher TNM stage. Risk of portal vein thrombosis 
was almost twice as much in cases with low expression of 
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ACTB when compared with tumors of high ACTB expres-
sion. Expression of ACTB was described as an independent 
prognostic factor in HCC patients, with low ACTB expres-
sion. HCCs being associated with poor patient survival (28).
Serum laminin γ2 monomer (Ln-γ2), a component of La-
minin-332 (Ln-332) trimer, is a novel marker for HCC. Earli-
er studies described the presence of monomeric Ln-γ2 in 
high quantities in aggressive variants of HCCs. Serum le-
vels of monomeric Ln-γ2 were analyzed in 57 patients with 
HCC, 24 patients with chronic liver disease and 52 healthy 
controls using chemiluminescent immunoassays (CLIA). 
Monomeric Ln-γ2 was highly elevated in samples of HCC 
patients compared to those with chronic liver disease and 
healthy controls. Serum AFP and desgamma-carboxypro-
thrombin (DCP) levels were also measured. Serum mono-
meric Ln-γ2 was described as a biomarker superior to AFP 
in the differential diagnosis of HCCs versus non-cancerous 
chronic liver disease. A combination of DCP and Ln-γ2 was 
found to have a higher chance of detecting HCCs in com-
parison to the combination of AFP and DCP, as well as any 
of the three markers separately (29).
Platelet-derived Growth Factor BB (PDGF-BB) is a cytokine 
of critical importance in the process of carcinogenesis. Pre- 
and postoperative serum PDGF-BB levels were measured 
in patients who underwent curative resection of HCCs and 
monitored for HCC recurrence. Patients who developed 
recurrent HCCs had significantly lower serum PDGF-BB 
levels both preoperatively and postoperatively compared 
to HCCs with high serum PDGF-BB. These findings could 
point to perioperative serum PDGF-BB levels as early pre-
dictors of HCC recurrence (30).
A recent study scrutinized the use of CTCs in differentia-
ting HCC from non-cancerous diseases of the liver. CTCs 
were assigned into 3 categories based on surface marker 
expression profiles determined via the use of CTC assays: 
epithelial (EpCAM, CK8, CK18, CK19), mesenchymal (Vi-
mentin, Twist) and mixed, with total CTC count also used 
as a parameter. Results indicated that total CTC counts 
were superior to the use of serum AFP levels in confirming 
or excluding the presence of HCC. Combined use of total 
CTC count and AFP provided better results than either 
methods alone, suggesting that CTC analysis could poten-
tially become a modality of HCC diagnosis equal or superi-
or to routine AFP measurements (31).
Examining CTCs as potential indicators of postoperative 
survival in HBV-associated HCCs found significant corre-
lations between preoperative CTC count and Edmondson 
stage. Lower postoperative CTC count and perioperative 
changes in CTC count were associated with higher prog-
ression-free survival (PFS), but no correlation was found 
with OFS. The most sensitive predictor of PFS was deter-
mined being the perioperative changes in CTC counts. Ho-
wever, there were no associations between CTC count and 
any clinicopathological features (32).
Cholangiocarcinoma (CCA)
The use of fluorescence-activated cell scanning (FACS) for 
the detection of tumor-associated microparticles (taMPs) 
was elaborated in the differentiation of hepatobiliary tu-
mors (HCC, CCA) from taMPs detectable in colorectal and 
lung cancers, as well as observing differences in the taMP 
profiles of cancerous and non-cancerous diseases of the 
liver, such as liver cirrhosis. Results showed that both ma-
jor categories of hepatobiliary tumors (HCC and CCA) were 
associated with elevated serum levels of AnnexinV+ Ep-
CAM+ CD147+ taMPs.
A marked decrease in postoperative serum levels of An-
nexinV+ EpCAM+ ASGPR1+ taMPs was also observed in 
patients who had undergone curative surgical resection 
of their liver malignancies. No such correlation was noted 
between liver cirrhosis without malignancy and Anne-
xinV+ EpCM+ ASGPR1+ taMPs (33).
Postoperative monitoring of residual tumor burden or 
recurrence could become a major task for liquid biopsi-
es. Minute quantities of detectable particles associated 
with the presence of cancer could serve as indicators of 
incomplete resection and/or relapse, potentially providing 
crucial information earlier than imaging studies and cur-
rently used tumor markers.
Peptidase Inhibitor 15 (PI15) was first described in human 
glioblastoma and neuroblastoma cells (34). Studies also dis-
covered that PI15 is absent from non-tumorous human liver 
tissue while being abundant in CCA and present, to a lesser 
degree, in HCC, patients with HBV and benign liver disease. 
These results prompted another study, in which blood PI15 
levels were described as a specific marker of CCA. Plasma 
PI15 levels were measured in 61 CCA patients, 72 patients 
with HCC, 45 patients with chronic HBV infection and 28 
cases of benign liver disease and quantified using ELISA. 
Concentration of PI15 was significantly higher in patients 
with HBV-negative, but not HBV-positive CCA when compa-
red with other sample groups, which suggested a role for 
PI15 as a potential diagnostic marker specific for CCA.
Simultaneous use of CA19-9 and PI15 was also investiga-
ted in this study, with the results showing increased ac-
curacy in diagnosing CCA and detecting postoperative 
residual tumor mass, further reinforcing the reliability of 
PI-15 as a potential diagnostic tool (35).
Colorectal cancer
It is established that pre- and post-treatment levels of 
CTCs in metastatic colorectal cancer are predictive of pa-
tient survival; in a 2008 publication by Cohen et al., higher 
detectable CTC levels prior to and following treatment in-
dicated poor progression-free and overall survival when 
compared with patients with lower CTC levels in a stu-
dy involving 430 patients. Differences between pre- and 
post-treatment CTC levels were also found to be of notable 
significance, with a “conversion” from a high baseline CTC 
level to a lower one following treatment being a predictor 
of better outcomes than that of those retaining high CTC 
posttreatment (36).
A Meta-analysis by Rahbari N, et al. concluded that the pre-
sence of CTCs in patients with colorectal malignancies is 
indicative of poor prognosis (37).
Hinz S, et al. observed that higher CK20 expression of CTCs 
is indicative of poor clinical outcome in CRC patients (38).
Hendricks A, et al. further described the successful use 
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of CK20 and EGFR detection in peripheral mononuclear 
blood cells (PMBCs) using RT-qPCR in preoperative blood 
samples of colorectal cancer patients (39).
Extracellular miR-21 levels were studied in patients with 
colorectal cancer. Results showed that elevated exosomal 
levels of hsa-miR-21 in colorectal cancer patients were in-
dicative of higher TNM status, liver metastases and poor 
prognosis when compared with patients exhibiting low 
levels of exosomal miR-21 (40).
Comparative study of cell-free DNA (ctDNA) and circulating 
tumor cell (CTC) detection in stage IV colorectal cancer obser-
ved that while cfDNA could be isolated from the samples of 
every patient included in the study, CTCs could only be detec-
ted in about one out of every three cases. Liquid biopsy find-
ings were compared with those from tissue samples, finding 
a concordance of over 80% between ctDNA and tissue samp-
les regarding RAS, BRAF and ERBB2 alterations (41).
This suggests that cell-free tumor DNA (cfDNA) might be 
present in higher, more reliably detectable quantities in 
blood samples of CRC patients than CTCs.
RAS mutation testing in liquid biopsy samples of patients 
with metastatic colorectal adenocarcinomas was found to 
have a concordance rate of 78.3% compared with tissue 
sample analysis (42).
Recent study of cfDNA sequencing in patients with me-
tastatic CRCs (mCRC) found that mutations of TP53, KRAS 
and APC genes detected in plasma samples are associa-
ted with metastasis formation and correlate with tumor 
markers (CEA, CA-19-9) and tumor size. This study used an 
amplicon-based NGS platform to look for mutations of 14 
genes covering a broad spectrum of possible genetic alte-
rations in CRCs. Multi-gene panels like this could potenti-
ally be used for monitoring response to chemotherapy in 
mCRC patients (43).
A study of exosomal ECM1 expression in blood samples 
taken from peripheral blood and tumor-draining mesen-
teric veins showed that exosomal ECM1 levels are ele-
vated in the mesenteric vein blood of CRC patients with 
relapses when compared with relapse-free individuals 
and healthy controls. However, obtaining samples from 
tumor-draining mesenterial veins is possible only during 
a surgery, an invasive procedure. Furthermore, levels of 
exosomal ECM1 in the mesenterial blood samples diffe-
red from those observed in peripheral blood: exosomal 
ECM1 expression in the peripheral blood of relapse-free 
patients was higher in comparison to both relapsed pati-
ents and controls (44).
Conclusions
Liquid biopsy is a collection of emerging non-invasive di-
agnostic methods with the potential to become a widely 
used tool in the management of cancer patients including 
screening, diagnosis and follow-up. However, further met-
hodological elaboration is needed, which must establish a 
library of verified biomarkers for each type of cancer.
Additionally, as it was demonstrated by the articles cited 
in this review, analysis of multiple circulating particles of 
more than just one type (e.g. proteins, cfRNA, cfDNA, exo-
somes etc.) is more strongly associated with correct diag-
nosis.
Thus, the liquid biopsies of the future will likely include 
panels that can quantify the expression of several bio-
markers. Used in tandem with already established moda-
lities of diagnosis and surveillance (e.g. imaging studies, 
tumor markers etc.), liquid biopsy could emerge as a cruci-
al method providing information regarding the clinicopat-
hology of tumors using non-invasive methods.
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